logo
Science Portal
Copyright © Médecins Sans Frontières
v2.1.5148.produseast1
About MSF Science Portal
About
Contact Us
Frequently Asked Questions (FAQs)
Privacy Policy
Terms of Use
Copyright © Médecins Sans Frontières
v2.1.5148.produseast1
The devil we know: is the use of injectable agents for the treatment of MDR-TB justified? | Journal Article / Research | MSF Science Portal
Journal Article
|Research

The devil we know: is the use of injectable agents for the treatment of MDR-TB justified?

Reuter A, Tisile P, von Delft D, Cox HS, Cox V, Ditiu L, Garcia-Prats AJ, Koenig SP, Lessem E, Nathavitharana R, Seddon JA, Stillo J, von Delft A, Furin J
Download

Similar Content
Loading...
Loading...
Loading...
Abstract
For decades, second-line injectable agents (IAs) have been the cornerstone of treatment for multidrug-resistant tuberculosis (MDR-TB). Although evidence on the efficacy of IAs is limited, there is an expanding body of evidence on the serious adverse events caused by these drugs. Here, we present the results of a structured literature review of the safety and efficacy of IAs. We review the continued widespread use of these agents in the context of therapeutic alternatives-most notably the newer TB drugs, bedaquiline and delamanid-and from the context of human rights, ethics and patient-centered care. We conclude that there is limited evidence of the efficacy of IAs, clear evidence of the risks of these drugs, and that persons living with MDR-TB should be informed about these risks and provided with access to alternative therapeutic options.

Languages

English
DOI
10.5588/ijtld.17.0468
Published Date
01 Nov 2017
PubMed ID
29037291
Journal
International Journal of Tuberculosis and Lung Disease
Volume | Issue | Pages
Volume 21, Issue 11
Issue Date
2017-11-01
Dimensions Badge